Search results
Showing 8551 to 8600 of 8900 results
Magtrace and Sentimag for locating sentinel lymph nodes (MIB263)
This advice has been updated and replaced by NICE healthtech guidance 642.
myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
This advice has been updated and replaced by NICE medical technologies guidance 68.
Space from Depression for treating adults with depression (MIB215)
This advice has been updated and replaced by NICE HealthTech guidance 675.
FibroScan for assessing liver fibrosis and cirrhosis in primary care (MIB216)
This advice has been updated and replaced by NICE healthtech guidance 682.
Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection (MIB247)
This advice has been updated and replaced by NICE guideline NG199.
This advice has been updated and replaced by NICE Healthtech guidance 615.
KardiaMobile for the ambulatory detection of atrial fibrillation (MIB232)
This advice has been updated and replaced by NICE healthtech guidance 606.
This advice has been updated and replaced by NICE healthtech guidance 602.
Endoluminal gastroplication for gastro-oesophageal reflux disease (IPG404)
Interventional procedures, IPG404 - Issued: July 2011 --> This guidance has been updated and replaced by NICE HealthTech guidance 661.
Interventional procedures, IPG418 - Issued: January 2012 --> This guidance has been updated and replaced by NICE HealthTech guidance 662.
This guidance has been replaced by NICE guideline NG17.
Farco-fill Protect for indwelling urinary catheterisation (MIB121)
July 2021: NICE has withdrawn the medtech innovation briefing (MIB) on Farco-fill Protect for indwelling urinary catheterisation because the product has been withdrawn from the UK market.
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
More than 7,000 people in England will now be able to access to a life-extending treatment for advanced bowel cancer.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
Learn how NICE healthtech guidance helped East London NHS Foundation Trust tackle rising demand for children's mental health services.
Newly recommended CBT therapies could help children and young people deal with anxiety
NICE conditionally recommends digital cognitive behaviour therapies (CBT) for use in the NHS to help children and young people with symptoms of mild to moderate anxiety
Seven digital platforms supporting at home cardiac rehab given conditional recommendations
People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 7 digital platforms for use in the NHS.
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
NICE's prioritisation process explained – what healthtech developers need to know
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
Our associate director of NICE Advice outlines his top tips for healthtech companies, helping them chart a clear path from innovation to NHS adoption.
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.
Accelerating innovation: How NICE is opening pathways to digital health technologies for the NHS
Following her appearance at this year’s HETT Show, programme director Sarah Byron tells us why the government’s 10 Year Plan is a game changer for healthtech and how we’re driving the changes at NICE.
New AI tools could help save lives by spotting warning signs of bowel cancer earlier
Five smart technologies that act as a "second pair of eyes" during bowel examinations have been conditionally recommended by NICE for NHS use, potentially helping doctors spot harmful growths that could turn into cancer.
Fertility clinics must end unproven treatments that don't help couples have babies
Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.
For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
Preparing for the next breakthroughs in liver disease treatments
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.
Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.
To support use of up-to-date content, and drive sustainability and digital transformation, the upcoming editions of BNF and BNFC (scheduled for distribution in October and November 2023) will be the last print editions to be supplied to the NHS in England by NICE.
People living with metastatic prostate cancer in England will gain access to a new treatment combination from today (Friday, 24 October), following a recommendation by NICE.
Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.
Pre-exposure prophylaxis (PrEP) became routinely available through sexual health clinics in 2020, with NICE recommending the tablets for people at high risk of HIV in 2021.
First HIV prevention injection for people unable to have daily PrEP recommended
A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.
Our chief executive, Dr Sam Roberts, welcomes the government's 10 Year Plan for healthcare
The government's 10 Year Plan marks a pivotal moment for healthcare and strengthens NICE’s role.
How NICE is helping to deliver the government's 10 Year Plan for healthcare
Home News Podcasts How NICE is helping to deliver the government's 10 Year Plan for healthcare Podcasts 30 September 2025 Listen About this
Tackling variation in rehab for people with neurological conditions
NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.
We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.
Same time decisions on licensing and value - what pharmaceutical companies need to know
Learn how NICE and MHRA are launching an aligned pathway to accelerate patient access to medicines and provide a more efficient route for industry.
NICE joins international collaboration on HTA methods research
We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.
NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this advanced healthcare training bridges clinical practice and system-wide decision-making through one committee member's transformative journey.
The new approach puts HealthTech on equal footing with medicines, ensuring innovations like wearable diabetes monitors and AI diagnostics reach patients faster and more consistently across the NHS.
Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery
New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
The new treatment offers hope to thousands living with advanced urothelial cancer, with clinical trials showing overall survival rates were almost twice as long compared to standard treatment.
First NICE-curated guideline announced ahead of World Duchenne Awareness Day
In the lead-up to World Duchenne Awareness Day on Sunday 7 September, we’re pleased to announce the completion of our first assessment of an externally developed clinical guideline.
Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
Home News Podcasts Innovation in action: Inside NICE's HTA Lab Podcasts 30 July 2025 Listen About this episode Our Health Technology Assessment